Showing 1681-1690 of 5771 results for "".
- OliX Pharmaceuticals Announces IND Submission to FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trialhttps://modernod.com/news/olix-pharmaceuticals-announces-ind-submission-to-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial/2480945/OiX Pharmaceuticals announced the submission of an investigational new drug (IND) application to the FDA to evaluate the safety and tolerability of OLX10212 for the treatment of advanced age-related macular degeneration (AMD). The objective of this phase 1 study is to determine the safety an
- Oculis Announces First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 in the Treatment of Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-announces-first-patient-enrolled-in-phase-3-optimize-trial-of-ocs-01-in-the-treatment-of-inflammation-and-pain-following-cataract-surgery/2480939/Oculis SA announced that the first patient has been enrolled in its phase 3 OPTIMIZE trial evaluating the efficacy and safety of once-daily OCS-01 for the treatment of inflammation and pain following cataract surgery. OCS-01 is a novel, high concentration, preservative-free, topical formulat
- Oyster Point Pharma Announces Restructuring Plan to Reduce Costshttps://modernod.com/news/oyster-point-pharma-announces-operating-expense-streamlining-plan/2480938/Oyster Point Pharma announced it will implement an operating expense streamlining plan that will include a reduction of employee and non-employee expenses across the organization. The company plans to continue to drive the launch of Tyrvaya with approximately 150-200 fie
- MeiraGTx Announces Topline Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Vision in XLRP Patientshttps://modernod.com/news/meiragtx-announces-positive-topline-data-from-the-mgt009-phase-12-clinical-study-demonstrating-safety-and-improvement-in-vision-in-xlrp-patients/2480936/MeiraGTx Holdings announced topline data from the phase 1/2 clinical study MGT009 (
- Graybug Announces Review of Strategic Alternativeshttps://modernod.com/news/graybug-announces-review-of-strategic-alternatives/2480935/Graybug Vision announced that its Board of Directors will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. As part of this process, the company will explore the potential for an acquisition, company sale, merger, divesti
- Kuria Therapeutics and Scohia Pharma Announce Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2 Activatorhttps://modernod.com/news/kuria-therapeutics-and-scohia-pharma-announce-licensing-agreement-for-ophthalmic-and-dermal-rights-to-sco-116-a-novel-nrf2-activator/2480933/Kuria Therapeutics and Japanese biotech company Scohia Pharma announced that the companies have entered into a licensing agreement under which Kuria may develop, manufacture, and commercialize worldwide the locally delivered formulations of SCO-116, one of Scohia's internally discov
- Kubota Vision Announces End-of-Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Diseasehttps://modernod.com/news/kubota-vision-announced-end-of-phase-3-clinical-trial-of-emixustat-in-patients-with-stargardt-disease/2480932/Kubota Vision announced today the completion of the phase 3 clinical trial investigating emixustat hydrochloride (emixustat) in patients with macular atrophy secondary to Stargardt disease. The study was a multicenter, randomized, double-masked, and placebo-controlled phase 3 clini
- Harrow Health Announces Launch of Iopidine 1% and Maxitrol in the United Stateshttps://modernod.com/news/harrow-health-announces-launch-of-iopidine-1-and-maxitrol-in-the-united-states/2480929/Harrow Health announced the completion of the transfer to Harrow of the new drug applications (NDAs) of recently acquired, FDA-approved ophthalmic medicines, Iopidine 1%, Maxitrol 3.5mg/10,000 units/0.1%, and Moxeza 0.5%. Harrow also announced that Iopidine 1% and Maxitrol are
- American Academy of Optometry Foundation Announces Inaugural Bright Ideas Pitch Competitionhttps://modernod.com/news/american-academy-of-optometry-foundation-announces-inaugural-bright-ideas-pitch-competition/2480927/The American Academy of Optometry Foundation (AAOF) has announced its inaugural "BRIGHT IDEAS Pitch Compe
- EyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of Uveitis Treatment Yutiq in Chinahttps://modernod.com/news/eyepoint-pharmaceuticals-and-ocumension-therapeutics-announce-approval-of-nda-by-chinas-nmpa-for-uveitis-treatment-yutiq/2480925/EyePoint Pharmaceuticals and OcuMension Therapeutics announced that China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has approved Yutiq (fluocinolone acetonide intravitreal implant) 0.18mg for the treatment of chr